share_log

eFFECTOR Therapeutics | 8-K: eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

eFFECTOR Therapeutics | 8-K: Current report

eFFECTOR Therapeutics | 8-K：重大事件
美股SEC公告 ·  2024/03/26 04:15

Moomoo AI 已提取核心信息

On March 25, 2024, eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced its financial results for the fourth quarter and full year ended December 31, 2023. The company reported a net loss of $9.1 million for the quarter and $35.8 million for the full year. Despite the losses, eFFECTOR highlighted significant progress in its clinical programs, including the expected early April 2024 release of topline data from the Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC). Additionally, the company reported a median progression-free survival of 7.4 months in a cohort evaluating zotatifin in combination with fulvestrant and abemaciclib in heavily pretreated patients with ER+ breast cancer. eFFECTOR also received U.S. FDA Fast Track designation for zotatifin in this patient population. The company raised $15.0 million in gross proceeds from registered direct financing, extending its cash runway into the first quarter of 2025. The financial report detailed R&D and G&A expenses, along with other income and expenses, and provided an update on the company's cash position and guidance.
On March 25, 2024, eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced its financial results for the fourth quarter and full year ended December 31, 2023. The company reported a net loss of $9.1 million for the quarter and $35.8 million for the full year. Despite the losses, eFFECTOR highlighted significant progress in its clinical programs, including the expected early April 2024 release of topline data from the Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC). Additionally, the company reported a median progression-free survival of 7.4 months in a cohort evaluating zotatifin in combination with fulvestrant and abemaciclib in heavily pretreated patients with ER+ breast cancer. eFFECTOR also received U.S. FDA Fast Track designation for zotatifin in this patient population. The company raised $15.0 million in gross proceeds from registered direct financing, extending its cash runway into the first quarter of 2025. The financial report detailed R&D and G&A expenses, along with other income and expenses, and provided an update on the company's cash position and guidance.
2024年3月25日，临床阶段的生物制药公司Effector Therapeutics, Inc. 公布了截至2023年12月31日的第四季度和全年财务业绩。该公司报告本季度净亏损910万美元，全年净亏损3580万美元。尽管亏损，但Effector还是强调了其临床项目的重大进展，包括预计于2024年4月初发布的托米沃舍替布联合pembrolizumab治疗非小细胞肺癌（NSCLC）的2b期KICKSTART试验的主要数据。此外，该公司报告称，在评估佐他替芬与氟维司朗和阿贝马西利布联合治疗的ER+乳腺癌患者中，无进展存活率中位数为7.4个月。Effector还获得了美国食品药品管理局对该患者群体中佐他替芬的快速通道认定。该公司通过注册直接融资筹集了1,500万澳元的总收益，将其现金流延至2025年第一季度。财务报告详细介绍了研发和并购费用以及其他收入和支出，并提供了公司的最新现金状况和指导。
2024年3月25日，临床阶段的生物制药公司Effector Therapeutics, Inc. 公布了截至2023年12月31日的第四季度和全年财务业绩。该公司报告本季度净亏损910万美元，全年净亏损3580万美元。尽管亏损，但Effector还是强调了其临床项目的重大进展，包括预计于2024年4月初发布的托米沃舍替布联合pembrolizumab治疗非小细胞肺癌（NSCLC）的2b期KICKSTART试验的主要数据。此外，该公司报告称，在评估佐他替芬与氟维司朗和阿贝马西利布联合治疗的ER+乳腺癌患者中，无进展存活率中位数为7.4个月。Effector还获得了美国食品药品管理局对该患者群体中佐他替芬的快速通道认定。该公司通过注册直接融资筹集了1,500万澳元的总收益，将其现金流延至2025年第一季度。财务报告详细介绍了研发和并购费用以及其他收入和支出，并提供了公司的最新现金状况和指导。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间